Dr Tatt Jhong Haw has over years of experience as pre-clinical Researcher in Cardio-Oncology and Respiratory health.

In the last 4 years, Dr Haw has managed and driven cardio-oncology research using a combination of animal models, in vitro cultures, and human inducible pluripotent stem cells-derived cardiomyocyte to discover the mechanisms of anti-cancer therapies-induced cardiotoxicity.
In addition, Dr Haw also managed and performed pre-clinical work with an industry partner, Race Oncology© (ASX: RAC) to investigating a novel therapeutic (Zantrene®) to mitigate chemotherapy-induced heart failures in cancer patients.

Dr Haw have also previously (2016-2020) managed and completed over 12 industry/commercial research projects partnering with prominent Australian and International pharmaceutical companies (Allakos, PharmAkea, AusBio, Pharmaxis and Genentech) to assess the therapeutic potential of several pre-clinical treatments in a mouse model of emphysema/COPD/influenza infection.